Pulse Biosciences has a November 5 earnings date: Pulse Biosciences stock gains 10.05 percent

Published on 10/20/2026 at 21:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 434,000. Pulse Biosciences stock costs EUR 46.00 on October 20, 2026, up 10.05 percent versus the Xetra close.

Reporting date November 5

Pulse Biosciences has an earnings date of November 5, 2026.
Second-quarter 2026 revenue reached USD 434,000, while net loss was USD 24.66 million.
Pulse Biosciences stock costs EUR 46.00 at Lang & Schwarz on October 20, 2026 at 9:49 p.m. CEST, 10.05 percent above the Xetra close of October 19, 2026.
Market capitalization was USD 3.6 billion, alongside a negative price-to-earnings ratio of 43.37.

PLSE, US74587B1017, Illustration mit AI erstellt.

Pulse Biosciences has an earnings date of November 5, 2026, according to Yahoo Finance. The stock was trading at EUR 46.00 at Lang & Schwarz on October 20, 2026 at 9:49 p.m. CEST, up 10.05 percent versus the Xetra close of October 19, 2026.

Second-quarter revenue stayed modest

Pulse Biosciences reported USD 434,000 in revenue for the second quarter of 2026, according to Benzinga. Net loss attributable to common shareholders was USD 24.66 million, or USD 0.36 per diluted share, while operating cash flow was negative USD 18.71 million in the same period.

The revenue figure was below the USD 566,660 consensus cited for the second quarter, while the adjusted loss of USD 0.36 per share exceeded the expected adjusted loss of USD 0.28, Investing.com reported.

Stock position after the move

On Nasdaq, Pulse Biosciences was last quoted at USD 50.79 on October 20, 2026 at 3:57 p.m. EDT. The same quote showed a USD 12.56 to USD 58.90 52-week range, placing the stock 13.77 percent below its yearly high and 304.46 percent above its yearly low.

Market capitalization stood at USD 3.6 billion, with a negative price-to-earnings ratio of 43.37. Trading volume was 273,105 shares against an average volume of 520,637 shares. Pulse Biosciences operates in healthcare and medical instruments and supplies, with its CellFX and Nano-Pulse Stimulation technologies aimed at medical applications.

What comes before the earnings date

The November 5, 2026 report is the next dated corporate event identified for the company. The investor-relations page describes Pulse Biosciences as a bioelectric medicine company and lists an August 2026 investor presentation as its latest presentation.

Analyst targets provide a separate valuation reference. Markets Insider reported on October 13, 2026 that Oppenheimer raised its target from USD 35.00 to USD 60.00 and kept an Outperform rating. The target was 18.10 percent above the Nasdaq price quoted in that report.

Comparison with peers

Pulse Biosciences: plus 10.05 percent versus the Xetra close, negative price-to-earnings ratio of 43.37, market capitalization USD 3.6 billion.

Edwards Lifesciences: plus 1.17 percent, price-to-earnings ratio 50.68, market capitalization USD 50.9 billion.

Boston Scientific: plus 1.23 percent, price-to-earnings ratio 18.50, market capitalization USD 66.1 billion.

Trading level and next date

Pulse Biosciences therefore combines a sharp euro-market move with a small second-quarter revenue base and a large quarterly loss. The November 5 reporting date will put the next revenue and cash-flow figures into the market calendar.

The further course of trading is shown by the continuously updated real-time quote of Pulse Biosciences stock.